Establishment of a Swiss webster mouse model of pneumonic plague to meet essential data elements under the animal rule

Clinical and Vaccine Immunology

Volumn 19, Issue 4, 2012, Pages 468-476

  Fellows, Patricia ^a   Lin, Winston ^b   Detrisac, Carol ^c   Hu, Shu Chieh ^b   Rajendran, Narayanan ^b   Gingras, Bruce ^b   Holland, Louis ^b   Price, Jessica ^a   Bolanowski, Mark ^a,d   House, Robert V ^a  

^a A CSC Company   (United States)

^b IIT RESEARCH INSTITUTE   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

^d PharmAthene Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM DETECTION; CLINICAL FEATURE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL ANIMAL WELFARE; EXPERIMENTAL INFECTION; FEMALE; HISTOPATHOLOGY; LD 50; MALE; NONHUMAN; NOSE PROVOCATION TEST; PATHOPHYSIOLOGY; PLAGUE; PNEUMONIA; PNEUMONIC PLAGUE; PRIORITY JOURNAL; SWISS WEBSTER MOUSE; YERSINIA PESTIS;

ANIMAL STRUCTURES; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LETHAL DOSE 50; MALE; MICE; PLAGUE; PLAGUE VACCINE; YERSINIA PESTIS;

EID: 84859346160     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05591-11     Document Type: Article

References (51)

1. Adamovicz JJ, Worsham PL. 2006. Plague, p 107-135. In Swearengen JR (ed), Biodefense research methods and animal models. CRC Press, Boca Raton, FL.
2. Agar SL, et al. 2008. Characterization of a mouse model of plague after aerosolization of Yersinia pestis CO92. Microbiology 154:1939-1948.
3. Anderson GW, Heath DG, Bolt CR, Welkos SL, Friedlander AM. 1998. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am. J. Trop. Med. Hyg. 58:793-799. (Pubitemid 28307401)
4. Andrews GP, Heath DG, Anderson GW, Welkos SL, Friedlander AM. 1996. Fraction 1 capsule antigen (f1) purification from Yersinia pestis CO92 and from Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect. Immun. 64:2180-2187. (Pubitemid 26167232)
5. Barry J. 1 February 1993. Planning a plague? Newsweek, p 40-41.
6. Bubeck SS, Cantwell AM, Dube PH. 2007. Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice. Infect. Immun. 75:697-705. (Pubitemid 46203431)
7. Burrows TW, Bacon GA. 1958. The effects of loss of different virulence determinants on the virulence and immunogenicity of strains of Yersinia pestis. Br. J. Exp. Pathol. 39:278.
8. Cavanaugh DC, Cadigan FC, Williams JE, Marshall JD. 1982. Plague. In Ognibene AJ, Barrett NO (ed), General medicine and infectious disease internal medicine in Vietnam, vol. 2. Office of the Surgeon General and Center of Military History, Washington, DC.
9. CDC. 8 November 2011, accession date. Emergency preparedness and response. CDC, Atlanta, GA. http://www.bt.cdc.gov/agent/agentlist-category.asp.
10. Center for Drug Evaluation and Research. 2009. Guidance for industry: animal models-essential elements to address efficacy under the Animal Rule. Food and Drug Administration, Department of Health and Human Services, Washington, DC. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM078923.pdf.
11. Cesta MF. 2006. Normal structure, function and histology of the spleen. Tox. Pathol. 34:455-465. (Pubitemid 44652213)
12. Chen TH, Meyer KF. 1974. Susceptibility and antibody response of Rattus species to experimental plague. J. Infect. Dis. 129(Suppl.):S62.
13. Chichester JA, et al. 2009. A single compound two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague. Vaccine 27:3471-3474.
14. Code of Federal Regulations. 2002. Title 21. Food and Drugs. Chapter I. Food and Drug Administration. Subpart H. Approval of biological products when human efficacy studies are not ethical or feasible. 21 CFR 601.91.
15. Cornelis GR. 2009. Molecular and cell biology aspects of plague. Proc. Natl. Acad. Sci. U. S. A. 97:8778-8783.
16. Cornelius CA, et al. 2008. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect. Immunol. 76:5588-5597.
17. Doll JM, et al. 1994. Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. Am. J. Trop. Med. Hyg. 51:109-114. (Pubitemid 24266296)
18. Feodorova VA, Corbel MJ. 2009. Prospects for new plague vaccines. Expert Rev. Vaccines 8:1721-1738.
19. Guyton ACN. 1947. Measurement of the respiratory volumes of laboratory animals. Am. J. Physiol. 150:70-77.
20. Heath DG, et al. 1998. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16:1131-1137. (Pubitemid 28307882)
21. Jawetz E, Meyer KF. 1944. The behavior of virulent and avirulent P. pestis in normal and immune experimental animals. J. Infect. Dis. 74:1.
22. Johnson D, Vincent J. 2003. Sampling and sizing of airborne particles. In DeNardi SR (ed), The occupational environment: its evaluation, control and management. American Industrial Hygiene Association, Fairfax, VA.
23. Lathem WW, Crosby SD, Miller VL, Goldman WE. 2005. Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. Proc. Natl. Acad. Sci. U. S. A. 102:17786-17791. (Pubitemid 41803575)
24. Leary SEC, et al. 1995. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect. Immun. 63:2854-2858.
25. Marshall JD, Jr, Bartelloni PJ, Cavanaugh DC, Kadull PJ, Meyer KF. 1974. Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine. J. Infect. Dis. 129(Suppl): S19-S25.
26. Mee C. 1990. How a mysterious disease laid low Europe's masses. Smithsonian 20:66-79.
27. Mett V, et al. 2007. A plant-produced plague vaccine candidate confers protection to monkeys. Vaccine 25:3014-3017. (Pubitemid 46482733)
28. Meyer KF, Cavanaugh DC, Bartelloni PJ, and Marshall JD, Jr. 1974. Plague immunization. I. Past and present trends. J. Infect. Dis. 129(Suppl):S13-S18.
29. Meyer KF. 1950. Immunity in plague: a critical consideration of some recent studies. J. Immunol. 64:139.
30. Morris SR. 2007. Development of a recombinant vaccine against aerosolized plague. Vaccine 25:3115-3117. (Pubitemid 46482764)
31. Nakajima R, Brubaker RR. 1993. Association between virulence of Yersinia pestis and suppressions of gamma interferon and tumor necrosis factor alpha. Infect. Immunol. 61:23-31. (Pubitemid 23015395)
32. National Research Council Institute of Laboratory Animal Resources. 1996. Guide for the Care and Use of Laboratory Animals. National Academies Press, Washington, DC.
33. Poland JD, Dennis DT. 1998. Plague, p 545-558. In Evans AS, Brachman PS (ed), Infectious diseases of humans: epidemiology and control. Plenum Press, New York, NY.
34. Pollitzer R. 1954. Plague. WHO Monogr. Ser. 22:1.
35. Rosenberg HF, Gallin JI. 1999. Inflammation. In Paul W (ed), Fundamental immunology. Lippincott-Raven, Philadelphia, PA.
36. Sha J, et al. 2008. Braun lipoprotein (Lpp) contributes to virulence of Yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect. Immun. 76:1380-1409.
37. Spivack ML, et al. 1958. The immune response of the guinea pigs to the antigens of Pasteurella pestis. J. Immunol. 80:132-141.
38. Stenseth NC, et al. 2008. Plague: past, present and future. PLoS Med. 5:9-13.
39. Stockham SL, Scott MA. 2002. Leukocytes. In Fundamentals of veterinary clinical pathology. Iowa State Press, Ames, IA.
40. Straley SC, Skrzpek E, Plano GV, Bliska JB. 1993. Yops of Yersinia spp. pathogenic for humans. Infect. Immun. 61:3105-3110. (Pubitemid 23223392)
41. United States Army Medical Research Institute of Infectious Diseases. 2005. Medical management of biological casualties handbook, 6th ed. United States Army Medical Research Institute of Infectious Diseases, Frederick, MD.
42. University of Minnesota. 8 November 2011, accession date. Reference values for laboratory animals. University of Minnesota, St. Paul, MN. http://www.ahc.umn.edu/rar/refvalues.html.
43. von Metz E, Eisler DM, Hottle GA. 1971. Immunogenicity of plague vaccines in mice and guinea pigs. Appl. Microbiol. 22:84.
44. Warren R, et al. 2011. Cynomolgus macaque model for pneumonic plague. Microb. Pathog. 50:12-22.
45. Welkos Davis SLKM, Pitt LM, Worsham PL, Friedlander AM. 1995. Studies on the contribution of the F1 capsule-associated plasmid pFra to the virulence of Yersinia pestis. Contrib. Microbiol. Immunol. 13:299-305.
46. Williams P, Wallace D. 1989. Unit 731: Japan's secret biological warfare in World War II. The Free Press, New York, NY.
47. Williams RC, Gewurz H, Quie PG. 1972. Effects of faction I from Yersinia pestis on phagocytosis in vitro. J. Infect. Dis. 126:235-241.
48. Williamson ED, et al. 2011. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague. Vaccine 29:4771-4777.
49. Williamson ED. 2009. Plague. Vaccine 27:D56-D60.
50. Williamson ED, et al. 1995. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immun. Med. Micro. 12:223-230.
51. World Health Organization. 8 November 2011, accession date. WHO, Geneva, Switzerland. www.who.int/mediacentre/factsheets/fs267/en/.